Advertisement

Annals of sex research

, Volume 6, Issue 2, pp 105–121 | Cite as

Serotonergic drug treatment of deviant sexual interests

  • J. Paul Fedoroff
Article

Abstract

The clinical English language literature on sexual deviance and treatment with serotonergic medications is reviewed. Evidence is presented to support the hypothesis that serotonergic medications decrease deviant sexual interests without impairing non-deviant sexual interests. Criteria for selecting which medication to prescribe are reviewed and the clinical data on response to treatment, time to treatment response, and relapse are summarized. Specific recommendations for the treatment of sexual deviance with serotonergic medications are given. Finally, recommendations for future research are described.

Keywords

Clinical Data Drug Treatment Treatment Response English Language Specific Recommendation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. APA. (1987).Diagnostic and statistical manual of mental disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association.Google Scholar
  2. APA. (1980). Tardive dyskinesia.American Journal of Psychiatry, 137, 163–172.Google Scholar
  3. Bartholomew, A.A. (1968). A long-acting phenothiazine as a possible agent to control deviant sexual behavior.American Journal of Psychiatry, 124, 917–923.Google Scholar
  4. Berlin, F., & Meinecke, C.F. (1981). Treatment of sex offenders with antiandrogenic medication: conceptualization, review of treatment modalities and preliminary findings.American Journal of Psychiatry, 138, 601–607.Google Scholar
  5. Bianchi, M.D. (1990). Fluoxetine treatment of exhibitionism.American Journal of Psychiatry, 147, 1089–1090.Google Scholar
  6. Bradford, J. (1983). The hormonal treatment of sexual offenders.Bulletin of the American Academy of Psychiatry and the Law, 11, 159–607.Google Scholar
  7. Bradford, J., & McLean, D. (1984). Sexual offenders, violence and testosterone.Canadian Journal of Psychiatry, 29, 335–343.Google Scholar
  8. Cesnik, J.A., & Coleman, E. (1989). Use of lithium carbonate in the treatment of autoerotic asphyxia.American Journal of Psychotherapy, XLIII, 277–286.Google Scholar
  9. Cesnik, J.A., & Coleman, E. (1990). Skoptic syndrome: The treatment of an obsessional gender dysphoria with lithium carbonate and psychotherapy.American Journal of Psychotherapy XLIV, 204–217.Google Scholar
  10. Coleman, E., Cesnik, J., Moore, A.M., & Dwyer, S.M. (1992). An exploratory study of the role of psychotropic medications in the treatment of sex offenders.Journal of Offender Rehabilitation, 18, 75–88.Google Scholar
  11. Davies, T.S. (1970). Cyproterone acetate in sexual misbehavior.Medicine, Science, and the Law, 10, 237–242.Google Scholar
  12. Davies, T.S. (1974). Cyproterone acetate for male hypersexuality.Journal of International Medical Research, 2, 159–163.Google Scholar
  13. Dickey, R. (1992). The management of a case of treatment resistant paraphilia with a long acting LHRH agonist.The Canadian Journal of Psychiatry, 37, 567–569.Google Scholar
  14. Egan, G.P., & Hammad, G.E.M. (1976). Sexual disinhibition with L-tryptophan.British Medical Journal, 2, 701.Google Scholar
  15. Emory, L.E., Cole, CM., & Meyer, W.J. (1992). The Texas experience with DepoProvera: 1980–1990.Journal of Offender Rehabilitation, 189, 125–139.Google Scholar
  16. Everitt, B.J. (1978). A neuroanatomical approach to the study of monoamines and sexual behavior. In J.B. Hutchison (Eds.),Biological determinants of sexual behavior (pp. 555–574). Chichester: John Wiley & Sons.Google Scholar
  17. Everitt, B.J., & Hansen, S. (1983). Catecholamines and hypothalamic mechanisms. In D. Wheatley (Eds.),Psychopharmacology and sexual disorders (pp. 3–14). Oxford: Oxford University Press.Google Scholar
  18. Fedoroff, J.P. (1988). Buspirone in the treatment of transvestic fetishism.Journal of Clinical Psychiatry, 49-408–409.Google Scholar
  19. Fedoroff, J.P. (1989). Buspirone and transvestic fetishism (reply to letter).Journal of Clinical Psychiatry, 50, 437.Google Scholar
  20. Fedoroff, J.P. (1992). Buspirone hydrochloride in the treatment of an atypical paraphilia.Archives of Sexual Behavior, 21, 401–406.Google Scholar
  21. Fedoroff, J.P., & Fedoroff, I.C. (1992). Buspirone and paraphilic sexual behavior.Journal of Offender Rehabilitation, 18, 89–108.Google Scholar
  22. Fedoroff, J.P., Wisner-Carlson, R., Dean, S., & Berlin, F.S. (1992). Medroxy-progesterone acetate in the treatment of paraphilic sexual disorders: Rate of relapse in paraphilic men treated with long-term group psychotherapy with or without medroxy-progesterone acetate.Journal of Offender Rehabilitation, 18, 109–123.Google Scholar
  23. Field, L.H. (1973). Benperidol in the treatment of sex offenders.Medicine, Science and the Law, 13, 195.Google Scholar
  24. Foote, R.M. (1944). Diethylstilbesterol in the management of psychopathological states in males.Journal of Nervous and Mental Disease, 99, 928–935.Google Scholar
  25. Gagne, P. (1981). Treatment of sex offenders with Medroxyprogesterone acetate.American Journal of Psychiatry, 160, 127–137.Google Scholar
  26. Garattini, S., Bonaccorsi, A., Jori, A., & Samanin, R. (1974). Appetite suppressant drugs: Past, present, and future. In L. Lasagna (Eds.),Obesity: Causes, consequences and treatment (pp. 70–80). New York: Medcom Press.Google Scholar
  27. Goldbloom, D.S., Kennedy, S. (1991). Adverse interaction of fluoxetine and cyproheptadine in two patients with bulimia nervosa.Journal of Clinical Psychiatry, 52, 261–262.Google Scholar
  28. Graf, K.J., & Eletreby, M.F. (1978). The role of the anterior pituitary gland in progestagen-induced proliferative mammary gland changes in the beagle.Arzneim. Forsch., 28, 54–58.Google Scholar
  29. Gurani, P.D., & Dwyer, M. (1986). Serum testosterone levels in sex offenders.Journal of Offender Counseling, Services and Rehabilitation, 11, 39–45.Google Scholar
  30. Herman, J.B., Brotman, A.W., Pollack, M.H., Falk, W.E., Biederman, J., & Rosenbaum, J.F. (1990). Fluoxetine-induced sexual dysfunction.Journal of Clinical Psychiatry, 51, 25–27.Google Scholar
  31. Hollander, E., & McCarley, A. (1992). Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers.Journal of Clinical Psychiatry, 53, 207–209.Google Scholar
  32. Hucker, S.J., Langevin, R., & Bain, J. (1988). A double blind trial of Provera for pedophiles.Annals of Sex Research, 1, 227–242.Google Scholar
  33. Hullin, R.P., & Jerram, T. (1976). Sexual disinhibition with L-trytophan.British Medical Journal, 2, 1010.Google Scholar
  34. Kafka, M.P. (1991a). Successful antidepressant treatment of nonparaphilic sexual addictions and paraphilias in men.Journal of Clinical Psychiatry, 52, 60–65.Google Scholar
  35. Kafka, M.P. (1991b). Successful treatment of paraphilic coercive disorder (a rapist) with fluoxetine hydrochloride.British Journal of Psychiatry, 158, 844–847.Google Scholar
  36. Kerbeshian, J., & Bird, L. (1991). Tardive syndrome and recurrent paraphilic masturbatory fantasy.American Journal of Psychiatry, 36, 155–157.Google Scholar
  37. Kline, M.D. (1989). Fluoxetine and anorgasmia.American Journal of Psychiatry, 146, 804–805.Google Scholar
  38. Kruesi, M.J.P., Fine, S., Valladares, L., Phillips, R.A., & Rapoport, J.L. (1992). Paraphilias: A double-blind crossover comparison of clomipramine versus desipramine.Archives of Sexual Behavior, 21, 587–593.Google Scholar
  39. Langevin, R., Bain, J., Ben-Aron, M.H., Coultard, R., Day, D., Handy, L., Heasman, G., Hucker, S.J., Purins, J.E., Roper, V., Russon, A.E., Webster, C.D., & Wortzman, G. (1985). Sexual aggression: Constructing a predictive equation. A controlled pilot study. In R. Langevin (Eds.),Erotic preference, gender identity and aggression in men. (pp. 39–76). Hillsdale, NJ: Lawrence Erlbaum Associates.Google Scholar
  40. Langevin, R., Paitich, D., Ramsay, G., Anderson, C., Kamrad, J., Pope, S., Geller, G., Pearl, L., & Newman, S. (1979). Experimental studies in the etiology of genital exhibitionism.Archives of Sexual Behavior, 8, 307–331.Google Scholar
  41. Langevin, R., Wright, P., & Handy, L. (1988). What treatment do sex offenders want?Annals of Sex Research, 1, 353–385.Google Scholar
  42. Laschet, U. & Laschet, L. (1971). Psychopharmacotherapy of sex offenders with cyproterone acetate.Pharmakopsychiatrie und Neuro-psychopharmakologie: Advances in Theoretical and Clinical Research, 4, 99–104.Google Scholar
  43. Laschet, U. (Ed.). (1973).Antiandrogen in the treatment of sex offenders: Mode of action and therapeutic outcome. Baltimore: Johns Hopkins University Press.Google Scholar
  44. Laschet, U., & Laschet, L. (1975). Antiandrogens in the treatment of sexual deviations in men.Journal of Steroid Biochemistry, 6, 821–826.Google Scholar
  45. Lorifice, L.S. (1991). Fluoxetine treatment of a fetish.Journal of Clinical Psychiatry, 52, 41.Google Scholar
  46. McCormick, S., Olin, J., Brotman, A.W. (1990). Reversal of fluoxetine-induced anorgsmia by cyproheptadine in two patients.Journal of Clinical Psychiatry, 51, 383–384.Google Scholar
  47. McLean, J.D., Forsythe, R.G., & Kaplan, L.A. (1983). Unusual side effects of clomipramine associated with yawning.Canadian Journal of Psychiatry, 28, 569–570.Google Scholar
  48. Meyerson, B.J., & Malmnas, C. (1978). Brain monoamines and sexual behavior. In J.B. Hutchinson (Eds.),Biological determinants of sexual behavior (pp. 521–554). Chichester: John Wiley & Sons.Google Scholar
  49. Modell, J.G. (1989). Repeated observations of yawning, clitoral enlargement, and orgasm associated with fluoxetine administration.Journal of Clinical Psychopharmacology, 9, 63–65.Google Scholar
  50. Money, J. (1970). Use of an androgen-depleting hormone in the treatment of male sex offenders.Journal of Sex Research, 6, 165–172.Google Scholar
  51. Monteiro, W.O., Novhirvani, H.F., Marks, I.M., & Lelliott, P.T. (1987). Anorgasmia from clomipramine in obsessive-compulsive disorder. A controlled trial.British Journal of Psychiatry, 151, 107–112.Google Scholar
  52. Pearson, H.J., Marshall, W.L., Barbaree, H.E., & Southmayd, S. (1992). Treatment of a compulsive paraphilic with buspirone.Annals of Sex Research, 5, 239–246.Google Scholar
  53. Perilstein, R.D., Lipper, S., & Friedman, L.J. (1991). Three cases of paraphilias responsive to fluoxetine treatment.Journal of Clinical Psychiatry, 52, 169–170.Google Scholar
  54. Price, J., & Grunhaus, L.J. (1990). Treatment of chlomipramine-induced anorgasmia with yohimbine: Case report.Journal of Clinical Psychiatry, 51, 32–33.Google Scholar
  55. Rada, R.T., Laws, D.R., Keller, R., Stivastava, L., & Peake, G. (1983). Plasma androgens in violent and non-violent sex offenders.Bulletin of the American Academy of Psychiatry and the Law, 11, 149–158.Google Scholar
  56. Ray, W.A., Griffin, M.R., Downey, W. (1989). Benzodiazepines of long and short elimination half-life and the risk of hip fracture.Journal of the American Medical Association, 252, 3303–3307.Google Scholar
  57. Rodenburg, M., Sheldon, L., & Owen, J.A. (1992). Sexual disinhibition with L-tryptophan.Canadian Journal of Psychiatry, 37, 666–667.Google Scholar
  58. Ruby, R., Brady, K.T., & Norris, G.T. (1993). Clomipramine treatment of sexual preoccupation.Journal of Clinical Psychopharmacology, 13, 158–159.Google Scholar
  59. Segraves, R.T. (1989). Effects of psychotropic drugs on human erection and ejaculation.Archives of General Psychiatry, 46, 275–284.Google Scholar
  60. Smith, B., & Prockop, D.J. (1962). Central nervous system effects of ingestion of L tryptophan by normal subjects.New England Journal of Medicine, 267, 1338–1341.Google Scholar
  61. Steele, T.E., & Howell, E.F. (1986). Cyproheptadine for imipramine-induced anorgasmia.Journal of Clinical Psychopharmacology, 6, 326–327.Google Scholar
  62. Sovner, S. (1984). Treatment of tricyclic antidepressant-induced orgasmic inhibition with cyproheptadine.Journal of Clinical Psychopharmacology, 4, 169.Google Scholar
  63. Stein, D.J., Hollander, E., Anthony, D.T., Schneier, F.R., Fallon, B.A., Liebowitz, M.R., & Klein, D.F. (1992). Serotonergic medications for sexual obsessions, sexual addictions, and paraphilias.Journal of Clinical Psychiatry, 53, 267–271.Google Scholar
  64. Sterkmans, P., & Geerts, F. (1966). Is benperidol (RF 504) the specific drug for the treatment of excessive and disinhibited sexual behavior?Acta Neurologica et Psychiatrica Belgica, 66, 1030–1040.Google Scholar
  65. Stevenson, R.W.D., & Solyom, L. (1990). The aphrodisiac effect of fenfluramine: Two case reports of a possible side effect to the use of fenfluramine in the treatment of bulimia.Journal of Clinical Psychopharmacology, 10, 69–71.Google Scholar
  66. Symmers, W. (1968). Carcinoma of the breast in transsexual individuals after surgery and hormonal interference with primary and secondary sex characteristics.British Medical Journal, 2, 83–85.Google Scholar
  67. Whittaker, L.H. (1959). Oestrogens and psychosexual disorders.Medical Journal of Australia, 2, 547–549.Google Scholar

Copyright information

© Juniper Press 1988

Authors and Affiliations

  • J. Paul Fedoroff
    • 1
  1. 1.Forensic DivisionThe Clarke Institute of PsychiatryTorontoCanada

Personalised recommendations